Paulino Eduardo, de Melo Andreia Cristina, de Andrade Diocésio Alves Pinto, de Almeida Michelle Samora
Brazilian National Cancer Institute, Rio de Janeiro, Brazil; Oncologia D'or, Rio de Janeiro, Brazil.
Brazilian National Cancer Institute, Rio de Janeiro, Brazil; Grupo Oncoclínicas, Rio de Janeiro, Brazil.
Crit Rev Oncol Hematol. 2023 Mar;183:103925. doi: 10.1016/j.critrevonc.2023.103925. Epub 2023 Jan 22.
Cervical cancer (CC) is a worldwide problem, especially in low- and middle-income countries, where patients are often diagnosed with locally advanced disease. Until recently, all chemotherapy drugs achieved low ORR and 12-month overall survival (12- month OS) for advanced CC after failure for platinum compounds. Advances in systemic therapy with immunotherapy, targeted therapy, and antibody-drug conjugates (ADC) have leveraged the 12-month OS limit. Recently, immunotherapy (pembrolizumab) has become the standard of care in first-line advanced CC combined with platinum and taxane and in second-line after platinum doublet failure.
宫颈癌是一个全球性问题，在低收入和中等收入国家尤为突出，这些国家的患者常常被诊断为局部晚期疾病。直到最近，所有化疗药物在铂类化合物治疗失败后的晚期宫颈癌治疗中，客观缓解率（ORR）都很低，12个月总生存率（12-month OS）也不高。免疫疗法、靶向疗法和抗体药物偶联物（ADC）等全身治疗方法的进展突破了12个月总生存率的限制。最近，免疫疗法（帕博利珠单抗）已成为一线晚期宫颈癌联合铂类和紫杉烷治疗以及铂类双联化疗失败后二线治疗的标准疗法。
